Department of Dermatology, Hôpital Erasme-ULB, Brussels, Belgium.
Department of Nephrology, Hôpital Erasme-ULB, Brussels, Belgium.
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:53-58. doi: 10.1111/jdv.17658.
It is well known that organ transplant recipients are prone to develop non-melanoma skin cancers, particularly cutaneous squamous cell carcinoma (cSCC). This is explained by the long-term use of immunosuppressants and thus the decrease of the immunosurveillance that protects from developing malignant tumours. Solid organ transplant recipients (SOTRs) are 65-250 times more likely to develop cSCC compared to the general population (Am J Transplant 2017; 17: 2509). Moreover, in these patients cSCCs follow a more aggressive course. Close follow-up and regular skin check-ups by a dermatologist are, therefore, crucial in the management of these patients. When detected early, cSCC can be easily and effectively treated by a simple excision. However, when advanced, outcomes are poor. Immune checkpoints inhibitors (ICIs) have been recently added to our arsenal and represent a breakthrough, having proved to be effective in achieving long-term responses. We, hereby, present two cases of difficult-to-treat cSCCs in renal transplanted patients.
众所周知，器官移植受者易发生非黑色素瘤皮肤癌，特别是皮肤鳞状细胞癌（cSCC）。这是由于长期使用免疫抑制剂，从而降低了保护免受恶性肿瘤发展的免疫监视。与普通人群相比，实体器官移植受者（SOTR）发生 cSCC 的可能性要高出 65-250 倍（Am J Transplant 2017; 17: 2509）。此外，在这些患者中，cSCC 的病程更为侵袭性。因此，对这些患者进行密切随访和皮肤科医生的定期皮肤检查至关重要。当早期发现时，cSCC 可以通过简单的切除轻松有效地治疗。但是，当病情进展时，预后较差。免疫检查点抑制剂（ICIs）最近已被添加到我们的武器库中，是一个突破，已被证明在实现长期反应方面有效。我们在此介绍了两名肾移植患者中难以治疗的 cSCC 病例。
